Advancing Kidney Research through CANN-NET
The Canadian Kidney Knowledge Translation and Generation Network (CANN-NET) was established in 2010 with the goal of bringing together Canadian kidney disease treatment guideline producers, knowledge translation specialists, and knowledge users to improve information sharing and care of patients with kidney disease.
CANN-NET brings together a national group of experienced Canadian researchers to address knowledge gaps by coordinating and executing multi-centre randomized trials. Kidney care and research priorities are identified by medical and administrative leads of renal programs across Canada. Currently, the network is focusing on the optimal timing of dialysis initiation and increasing the appropriate use of home dialysis.
The Kidney Foundation of Canada and the Canadian Society of Nephrology (CSN) are funding partners of CANN-NET. Dr. Braden Manns is both the newly-elected President (2014-2016) of the CSN and Chair of the CANN-NET Executive Committee.
Between 2004 and 2010, Dr. Braden Manns was Chair of the Canadian Society of Nephrology (CSN) Scientific Committee and an Associate Professor in the Departments of Medicine and Community Health Services at the University of Calgary. “At the time, I was frustrated by what I perceived to be a lack of collaboration between researchers and decision makers – all of which was resulting in gaps in care, and making it more difficult to undertake more multi-center clinical trials,” says Dr. Manns. So when a funding opportunity arose with the Canadian Institute for Health Research (CIHR), he worked with a group of investigators to prepare a submission that resulted in what has become the Canadian Kidney Knowledge Translation and Generation Net.
Identifying clinical trial priorities
Today, various committees guide CANN-NET’s extensive work and Dr. Manns chairs the network. “One large part of our work consists of trying to facilitate investigator-initiated clinical trials. We asked heads of renal programs and other knowledge users what they thought were the most important clinical trials to be done. Two trials were developed from identified priorities: one on the optimal way to manage people with high phosphorous levels on dialysis, and the other on the best way to manage high blood pressure in dialysis patients.”
To learn more about CANN-NET and other important networks, read our Spotlight on Research Networks newsletter.
For the Terms of Reference, please click on the name of the Committee in the organizational chart: